CMS-121 Capsules Canada — Capsules
Fisetin-Derived Research Compound
CMS-121 is a small-molecule compound derived structurally from the flavonoid fisetin. It is supplied as a laboratory research chemical and is handled only within controlled experimental settings.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
CMS-121 is a small-molecule compound derived structurally from the flavonoid fisetin. It is supplied as a laboratory research chemical and is handled only within controlled experimental settings.
The published record for CMS-121 specifically is limited. The compound is generally discussed in the context of acetyl-CoA carboxylase and lipid metabolism research, an area in which the available candidate literature examines the enzyme and its regulatory pathways rather than this compound directly.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
CMS-121 is described in the wider research context as a fisetin-derived molecule associated with acetyl-CoA carboxylase 1 (ACC1) and downstream lipid metabolic signaling. The candidate literature available here characterises that pathway rather than the compound: acetyl-CoA carboxylase activity has been studied in relation to lipid accumulation, mitochondrial function, and the AMPK, PPARα and CPT1A signaling axis in translational models, and ACC1 phosphorylation has been examined in endothelial cell dysfunction models under diabetic conditions.
Because the references supplied address the enzymatic target and its regulation rather than CMS-121 itself, the compound's own receptor or enzyme binding profile, potency, and pharmacological behaviour are not documented in this reference set. Research endpoints that can be described from the available record are limited to pathway-level measures: lipid accumulation, mitochondrial function markers, ACC phosphorylation state, and endothelial cell behaviour in vitro.
The origin and development history of CMS-121 are not well documented in the references available for this page. The compound is commonly identified as a synthetic derivative of the flavonoid fisetin, but no source in this reference set describes its synthesis, the group responsible, or the timeline of its characterisation.
The surrounding research area has developed independently of the compound. Work on acetyl-CoA carboxylase has examined its role in lipid accumulation and mitochondrial function, and more recent investigations have looked at regulation of ACC1 phosphorylation by noncoding RNA in endothelial models. Any account of how CMS-121 entered this literature cannot be established from the material available here.
CMS-121 appears in research frameworks concerned with acetyl-CoA carboxylase and lipid metabolic regulation. The literature available for this page examines that pathway at the enzyme level, covering lipid accumulation and mitochondrial function through the AMPK, PPARα and CPT1A axis, and ACC1 phosphorylation in endothelial cell models. Direct experimental data on CMS-121 itself is not represented in this reference set, and the published record for the compound should be treated as thin.
4 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Chen 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Dong 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Dong 2024, Chen 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Chen 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 2 primary papers published between 2024 and 2025 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
CMS-121 Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for CMS-121 Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
CMS-121 Capsules is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under acetyl-CoA carboxylase pathway research, lipid accumulation models and mitochondrial function studies.
The 2 papers cited on this page, published between 2024 and 2025 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. CMS-121 Capsules rests on 2 cited papers (between 2024 and 2025). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of CMS-121 Capsules is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy CMS-121 Capsules in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
CMS-121 Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains the labeled quantity of CMS-121. Independent third-party analysis verifies purity, identity, and net content per batch.
The vial contains only the compound. Any laboratory materials required for handling, solubilisation, or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis
PubMedLong noncoding RNA ZRANB2-AS2 promotes endothelial cell dysfunction by inhibiting phosphorylation of acetyl-CoA carboxylase 1 in diabetes
PubMedRelated
Eppix Flash Sale −30%Capsules
PDE5 Inhibitor Research Compound Tadalafil is a small-molecule phosphodiesterase type 5 (PDE5) inhibitor supplied in capsule form for laboratory research. It is handled as a reference compound in controlled experimental and analytical settings.
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Capsules
AMPA Receptor Potentiator TAK-653 is a small molecule described in the literature as an AMPA receptor positive allosteric modulator. It is supplied in capsule form strictly for laboratory research use.
$66.47$94.95CAD
Flash sale ends in
Eppix Flash Sale −30%Capsules
Unidentified Capsule Preparation SANA Capsules is supplied as a capsule-format research item. No molecular identity, sequence, or defined active constituent could be established for this designation from the available chemical records or published literature.
$66.47$94.95CAD
Flash sale ends in
Eppix Flash Sale −30%Capsules
Oral Non-Peptide GLP-1 Receptor Agonist Orforglipron is an orally available, non-peptide small molecule characterised as an agonist at the glucagon-like peptide-1 (GLP-1) receptor. It is supplied here in capsule form for laboratory research within controlled experimental environments.
$52.46$74.95CAD
Flash sale ends in
